The role of cytokines and their antagonists in the treatment of COVID‐19 patients

Z Mohseni Afshar, M Barary… - Reviews in medical …, 2023 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) has various presentations, of which
immune dysregulation or the so‐called cytokine storm syndrome (COVID‐CSS) is …

[HTML][HTML] The role of Interleukin 6 inhibitors in therapy of severe COVID-19

E Nasonov, M Samsonov - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

Modulation of Covid‐19 cytokine storm by tocilizumab

A Boretti, B Banik - Journal of Medical Virology, 2022 - Wiley Online Library
Abstract Coronavirus disease 2019 (Covid‐19) is the illness caused by severe acute
respiratory syndrome coronavirus 2, first identified in Wuhan, China at the end of 2019. On …

Anti-cytokine therapy in novel coronavirus disease (COVID-19)–the first administration of tocilizumab in Hungary at a department of infectology

B Lakatos, L Gopcsa, E Gondos, A Riczu, Z Várnai… - Orvosi …, 2020 - europepmc.org
During the past few months, a pandemic originating from China named new coronavirus
disease (COVID-19) has shown how vulnerable the world is. To date, no medication …

Cytokine storm in COVID-19: the current evidence and treatment strategies

Y Tang, J Liu, D Zhang, Z Xu, J Ji, C Wen - Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …

Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19

JJ Chen, LN Zhang, H Hou… - Experimental and …, 2021 - spandidos-publications.com
A severe immune response in patients with coronavirus disease 2019 (COVID‑19) can
cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine …

Therapeutic role of tocilizumab in SARS-CoV-2-induced cytokine storm: rationale and current evidence

C Pelaia, C Calabrese, E Garofalo, A Bruni… - International Journal of …, 2021 - mdpi.com
Among patients suffering from coronavirus disease 2019 (COVID-19) syndrome, one of the
worst possible scenarios is represented by the critical lung damage caused by the severe …

Interleukin-6 antagonists: Lessons from cytokine release syndrome to the therapeutic application in severe COVID-19 infection

J Meanwatthana, T Majam - Journal of Pharmacy Practice, 2022 - journals.sagepub.com
Current retrospective data have found up to 20% of COVID-19 infection had developed into
severe cases with hyperinflammatory pulmonary symptoms. Interleukin 6 (IL-6) is …

Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID‐19 pneumonia patients

B Borku Uysal, H Ikitimur, S Yavuzer… - Journal of medical …, 2020 - Wiley Online Library
To recognize the period of exaggerated cytokine response in patients with coronavirus
disease 2019 (COVID‐19) pneumonia, and to describe the clinical outcomes of using …

[PDF][PDF] The effect of tocilizumab on severe COVID-19 infection: Review of current evidence

A Cemal, H İNÖNÜ - Tuberk Toraks, 2021 - tuberktoraks.org
The COVID-19 outbreak that spread in December 2019 has caused the death of millions of
people in a short time. Many studies published recently have shown that many cytokines …